Fig. 7From: Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomesSignificantly enriched signaling pathways in NFE2L2-MU (A), Nrf2-activating MU (B) and Nrf2-inactivating MU patients with NSCLC in TCGA cohort. GSEA: gene set enrichment analysis; NES: normalized enrichment scoresBack to article page